Jue Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jue Wang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Peng Zhang
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
28 shared publications - Chenfei Wang
Tongji University
27 shared publications - Jiamin Zhang
Tongji University
27 shared publications - Jingxin Fu
Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
27 shared publications - Qin Tang
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
27 shared publications - Qiu Wu
Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Department of Orthopedics, Tongji Hospital, School of Life Science and Technology, Tongji University, Shanghai, China
27 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (33)
Proteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy
Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare yet highly aggressive subtype of non-small cell lung carcinoma (NSCLC) with limited therapeutic options. We conduct a comprehensive proteogenomic analysis of LCNEC using tumors and paired normal adjacent tissues from 107 patients (81 pure LCNEC and 26 combined LCNEC). APOBEC mutational signatures strongly correlate processes of tumor initiation and immune suppression, and KEAP1 mutations correlate with metabolic reprogramming in LCNEC combined with NSCLC. A conflicting relationship is observed between neuroendocrine and immune phenotypes. We identify three LCNEC subtypes with unique prognosis features, microenvironment dysregulation, genetic alterations, and potential therapeutic targets. Interleukin-33 (IL-33) emerges as a critical therapeutic biomarker associated with enhanced T cell infiltration and antitumor activity. We further optimize recombinant IL-33 (rIL33) with site-directed mutagenesis and develop PEGylated rIL33, demonstrating its prolonged circulation time in cynomolgus monkeys and superior immune agonist activity in mouse models. Overall, this study offers insights into LCNEC biology and provides promising innovative immunoagonist therapy strategies for lung cancer.
- 14 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (33)
Open AccessProteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy
Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare yet highly aggressive subtype of non-small cell lung carcinoma (NSCLC) with limited therapeutic options. We conduct a comprehensive proteogenomic analysis of LCNEC using tumors and paired normal adjacent tissues from 107 patients (81 pure LCNEC and 26 combined LCNEC). APOBEC mutational signatures strongly correlate processes of tumor initiation and immune suppression, and KEAP1 mutations correlate with metabolic reprogramming in LCNEC combined with NSCLC. A conflicting relationship is observed between neuroendocrine and immune phenotypes. We identify three LCNEC subtypes with unique prognosis features, microenvironment dysregulation, genetic alterations, and potential therapeutic targets. Interleukin-33 (IL-33) emerges as a critical therapeutic biomarker associated with enhanced T cell infiltration and antitumor activity. We further optimize recombinant IL-33 (rIL33) with site-directed mutagenesis and develop PEGylated rIL33, demonstrating its prolonged circulation time in cynomolgus monkeys and superior immune agonist activity in mouse models. Overall, this study offers insights into LCNEC biology and provides promising innovative immunoagonist therapy strategies for lung cancer.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Single-strand break repair genes (sheet1), double-strand break repair genes (sheet2), and DNA methylation related genes (sheet3).
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Single-strand break repair genes (sheet1), double-strand break repair genes (sheet2), and DNA methylation related genes (sheet3).
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Expression of DSB repair genes especially resistant or non-resistant DSB repair genes in TCGA datasets with SSB repair genes mutation and deletion.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Expression of DSB repair genes especially resistant or non-resistant DSB repair genes in TCGA datasets with SSB repair genes mutation and deletion.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
IFN-γ sensitivity of cancer cells (n = 43) from CCLE (sheet1); Gene sets enrichment for highly expressed gene sets in IFN-γ resistant/sensitive cell lines using CCLE transcriptomic dataset (sheet2-3).
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
IFN-γ sensitivity of cancer cells (n = 43) from CCLE (sheet1); Gene sets enrichment for highly expressed gene sets in IFN-γ resistant/sensitive cell lines using CCLE transcriptomic dataset (sheet2-3).
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Beta score (sheet1), mapping ratio (sheet2), and essential genes list (sheet3) of CRISPR screens.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Beta score (sheet1), mapping ratio (sheet2), and essential genes list (sheet3) of CRISPR screens.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Genes’ average Δβ-scores across all cancer cell lines (sheet1); Gene sets enrichment for positively (sheet2) / negatively (sheet3) selected genes in CRISPR screen. GSEA was used to perform the enrichment analysis; sgRNA sequences of AAVS1, PAXIP1, TP53BP1, XRCC4, RAD50, RAD51, BRCA1, BRCA2 (sheet4).
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Genes’ average Δβ-scores across all cancer cell lines (sheet1); Gene sets enrichment for positively (sheet2) / negatively (sheet3) selected genes in CRISPR screen. GSEA was used to perform the enrichment analysis; sgRNA sequences of AAVS1, PAXIP1, TP53BP1, XRCC4, RAD50, RAD51, BRCA1, BRCA2 (sheet4).
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Table S4 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Table S4 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S7 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Cox regression model of IFNG expression on patients’ survival in TCGA and Available expression data of ICB treatment.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway Activity
Cox regression model of IFNG expression on patients’ survival in TCGA and Available expression data of ICB treatment.